## 3 Data and Cohort  
Second-generation drug-eluting stents are considered gold-standard devices in stent surgery, with an overall TLF rate of 7% [23]. Bioresorbable stent technology is the fourth revolution in interventional cardiology [24], and is designed to address medical shortcomings of drug-eluting stents; their purpose is to fully support the vessel during the critical period, and then be resorbed by the body when no longer needed. The TLF rate of first-generation bioresorbable stents (with a poly-L-lactic acid polymer backbone, e.g., ABSORB biosensorable vascular scaffolds (Abbott Vascular) [25]) is reported to be about 8-11% [26]. For second-generation bioresorbable stents (with a magnesium alloy backbone, e.g., Magmaris sirolimus-eluting bioresorbable stents (Biotronik AG, Bulach, Switzerland)), the TLF rate is reported to be about 3.3-6.8% [27].  
The Magmaris stent consists of a limus family drug and a bioabsorbable polymer matrix, which achieves a controlled drug release for up to 90 days [28]. They are available in diameter ranges of 3.0-3.5 mm and lengths of 15 mm, 20 mm, and 25 mm. Pre- and post-dilatation are mandatory, for which a non-compliant balloon with a 1:1 balloon-to-arterly ratio is used. The residual stenosis after pre-dilatation should not exceed 20.0% [29].  
Cohort: In the BIOSOLVE-IV prospective study, we collect data from Magmaris implantations in adult patients (age > 18) between September 2016 and 2025 (last enrolled in July 2020). Each patient is followed up for up to five years. This study is being conducted in more than 120 medical centers in over 25 countries in Europe, Asia, Africa, and Australia/New Zealand [30]. The main inclusion criteria are target lesion stenosis >50.0% and <100.0%, thrombolysis in myocardial infarction (TIMI) flow \(\geq\)1, and a reference vessel diameter of 2.7-3.7 mm by visual estimation. However, the study also includes complex lesions except for occlusions. The main exclusion criteria are pregnancy, dialysis, left main coronary artery disease, restenotic lesions, or acute ST-elevated myocardial infarction [30]. Figure S1 shows an overview of the BIOSOLVE-IV prospective study.  
Data Elements: In the supplementary document, Tables S2-S7 show detailed statistical descriptions of the 86 data elements and feature characteristics for the cohort used for this analysis. Here in the main manuscript, Table 2 shows a summary of those features, following the timeline of the data collection per individual. The pre-intervention data (Table S2) include demographics, physical examinations, medical history, risk factors, and questionnaires. All events during the intervention are reported in Table S3. In addition, lesion characteristics and the Magmaris implantation itself are documented very closely (Table S4). Between the end of the procedure and hospital discharge, concomitant medication (Table S5), in accordance with the hospital standard of care, laboratory values, and ischemic status (Table S6) are also documented. After the procedure, all patients undergo follow-up evaluations at six months, twelve months, and annually after that, for up to five years. At each follow-up, data on the status of ischemia/angina, adverse events, and questionnaires are collected. Most of the features show an overall low missingness rate (Figure S2).  
Until July 2020, there were 2066 patients enrolled in the BIOSOLVE-IV study. We excluded patients with a missingness rate higher than 50% (\(n\) = 3) (Figure S2) and patients treated with more than one Magmaris stent (\(n\) = 85). We included all TLF patients. The remaining 1975 patients were used for analysis. In the cohort (\(n\) = 1975), there is a total of 163 patients with TLF (8.25%): 151 patients had TLF before end of Phase I, and 12 afterwards, and 84.14% of all TLF events happened within the first year after implantation. For patients with multiple TLF events (\(n\) = 4), we only considered the time of their first event.